Literature DB >> 24100523

Pulmonary inflammatory myofibroblastic tumor and IgG4-related inflammatory pseudotumor: a diagnostic dilemma.

Priyanka Bhagat1, Amanjit Bal, Ashim Das, Navneet Singh, Harkant Singh.   

Abstract

IgG4-related inflammatory pseudotumor (IPT) and inflammatory myofibroblastic tumor (IMT) share morphological features like a prominent fibroblastic/myofibroblastic proliferation and the presence of inflammatory cells. Since IPT is managed conservatively and IMT is treated by surgical excision, it is important to differentiate these two lesions. The aim of this study is to highlight morphological and immunohistochemical features that distinguish IPT and IMT. Clinicopathological characteristics of cases diagnosed as pulmonary IPT or IMT from 1997 to 2013 were reviewed. The histological features were studied on hematoxylin and eosin-stained sections. Immunohistochemistry was done for IgG, IgG4, ALK-1, SMA, desmin, and CD34 for classification into IPT and IMT. Of the ten patients, seven were male and the age ranged from 4 to 58 years. The tumor size ranged from 1.5 to 4.0 cm in diameter. Histologically, proliferation of bland-looking spindle cells along with fibrosis and an inflammatory infiltrate comprising of lymphocytes and plasma cells were the common morphological features of both lesions. The spindle cell proliferation was more marked in IMT whereas lymphoplasmacytic infiltrate was more prominent in IPT. Obstructive phlebitis was observed only in cases of IPT. IgG4 expression was noted in IPT, and the number of IgG4-positive plasma cells and the ratio of IgG4+/IgG+ plasma cells were significantly lower in IMT than in IgG4-related IPT. Expression of anaplastic lymphoma kinase (ALK) was observed only in IMT, but not in IgG4-related IPT. The proportion of proliferating spindle cells, lymphoplasmacytic infiltrate, obstructive phlebitis, IgG4+ plasma cells and the ratio of IgG4+/IgG+ plasma cells, and ALK expression are helpful in differentiating these morphologically similar but biologically different lesions, which require different treatment modalities.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24100523     DOI: 10.1007/s00428-013-1493-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  11 in total

Review 1.  IgG4-related disease.

Authors:  John H Stone; Yoh Zen; Vikram Deshpande
Journal:  N Engl J Med       Date:  2012-02-09       Impact factor: 91.245

Review 2.  Pathological features of IgG4-related sclerosing disease.

Authors:  Thomas C Smyrk
Journal:  Curr Opin Rheumatol       Date:  2011-01       Impact factor: 5.006

3.  Inflammatory myofibroblastic tumor: cytogenetic evidence supporting clonal origin.

Authors:  L D Su; A Atayde-Perez; S Sheldon; J A Fletcher; S W Weiss
Journal:  Mod Pathol       Date:  1998-04       Impact factor: 7.842

4.  Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor.

Authors:  J A Bridge; M Kanamori; Z Ma; D Pickering; D A Hill; W Lydiatt; M Y Lui; G W Colleoni; C R Antonescu; M Ladanyi; S W Morris
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

5.  IgG4 plasma cells in inflammatory myofibroblastic tumor: inflammatory marker or pathogenic link?

Authors:  Shahrazadb T Saab; Jason L Hornick; Christopher D Fletcher; Sandra J Olson; Cheryl M Coffin
Journal:  Mod Pathol       Date:  2011-02-04       Impact factor: 7.842

Review 6.  Successful treatment of inflammatory myofibroblastic tumor with malignant transformation by surgical resection and chemotherapy.

Authors:  Megan K Dishop; Brad W Warner; Louis P Dehner; Vesna M Kriss; Martha F Greenwood; John D Geil; Jeffrey A Moscow
Journal:  J Pediatr Hematol Oncol       Date:  2003-02       Impact factor: 1.289

7.  Inflammatory myofibroblastic tumor versus IgG4-related sclerosing disease and inflammatory pseudotumor: a comparative clinicopathologic study.

Authors:  Hidetaka Yamamoto; Hiroshi Yamaguchi; Shinichi Aishima; Yoshinao Oda; Kenichi Kohashi; Yumi Oshiro; Masazumi Tsuneyoshi
Journal:  Am J Surg Pathol       Date:  2009-09       Impact factor: 6.394

8.  IgG4-related lung and pleural disease: a clinicopathologic study of 21 cases.

Authors:  Yoh Zen; Dai Inoue; Azusa Kitao; Manabu Onodera; Hitoshi Abo; Shiro Miyayama; Toshifumi Gabata; Osamu Matsui; Yasuni Nakanuma
Journal:  Am J Surg Pathol       Date:  2009-12       Impact factor: 6.394

9.  Inflammatory myofibroblastic tumor of the lung.

Authors:  Hiroyuki Sakurai; Tadashi Hasegawa; Shun ichi Watanabe; Kenji Suzuki; Hisao Asamura; Ryosuke Tsuchiya
Journal:  Eur J Cardiothorac Surg       Date:  2004-02       Impact factor: 4.191

10.  Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases.

Authors:  Cheryl M Coffin; Jason L Hornick; Christopher D M Fletcher
Journal:  Am J Surg Pathol       Date:  2007-04       Impact factor: 6.394

View more
  15 in total

1.  Inflammatory Myofibroblastic Tumor of the Nasal Cavity.

Authors:  Rachel L Werner; James T Castle
Journal:  Head Neck Pathol       Date:  2015-10-19

2.  Pulmonary pseudo-tumour, aortitis and IgG4 disease.

Authors:  A Córdoba; M Lisa; J Gómez-Román; J L Hernández
Journal:  QJM       Date:  2016-01-19

3.  Pulmonary inflammatory myofibroblastic tumor mimics lung cancer.

Authors:  Jing Yu; Weidong Li; Dong Li; Zhang Zhang; Tielian Yu
Journal:  Thorac Cancer       Date:  2014-04-22       Impact factor: 3.500

4.  Pulmonary inflammatory myofibroblastic tumor versus IgG4-related inflammatory pseudotumor: differential diagnosis based on a case series.

Authors:  Longfei Zhu; Jian Li; Chengwu Liu; Wenshuang Ding; Feng Lin; Chenglin Guo; Lunxu Liu
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

5.  Mass-forming immunoglobulin G4-related disease shows indolent clinical course after surgical resection, clinicopathological analysis of a series of 15 cases.

Authors:  Ruoyu Shi; Benjamin Livingston Farah; Chuanhui Xu; Joe Poh Sheng Yeong; Chik Hong Kuick; Jian Yuan Goh; Kenneth Tou En Chang; Angela Takano
Journal:  Virchows Arch       Date:  2021-10-07       Impact factor: 4.064

6.  Morphologic Overlap Between Inflammatory Myofibroblastic Tumor and IgG4-related Disease: Lessons From Next-generation Sequencing.

Authors:  Martin S Taylor; Abhijit Chougule; Allsion R MacLeay; Pawel Kurzawa; Ivan Chebib; Long Le; Vikram Deshpande
Journal:  Am J Surg Pathol       Date:  2019-03       Impact factor: 6.394

7.  High fever as an initial symptom of primary gastric inflammatory myofibroblastic tumor in an adult woman.

Authors:  Jiang-Feng Qiu; Yi-Jiu Shi; Lei Fang; Hui-Fang Wang; Mou-Cheng Zhang
Journal:  Int J Clin Exp Med       Date:  2014-05-15

8.  Inflammatory myofibroblastic tumor of the lung in pregnancy mimicking carcinoid tumor.

Authors:  Venkata Nagarjuna Maturu; Amanjit Bal; Navneet Singh
Journal:  Lung India       Date:  2016 Jan-Feb

Review 9.  Current management of pediatric soft tissue sarcomas.

Authors:  Surasak Sangkhathat
Journal:  World J Clin Pediatr       Date:  2015-11-08

10.  Inoperable inflammatory myofibroblastic tumour of the para-nasal sinuses and orbit with recurrence responding to methotrexate and prednisolone: a case report.

Authors:  Mitrakrishnan Rayno Navinan; Isurujith Liyanage; Sandamalee Herath; Jevon Yudhishdran; Chrishan Shivanthan; Dulani Beneragama; Aruna Kulatunga
Journal:  BMC Res Notes       Date:  2015-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.